Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study). (2018)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41416-018-0123-9
PubMed Identifier: 30131546
Publication URI: http://europepmc.org/abstract/MED/30131546
Type: Journal Article/Review
Volume: 119
Parent Publication: British journal of cancer
Issue: 9
ISSN: 0007-0920